RESULTS	Patients treated with NaP tablets experienced significantly fewer adverse events ( 66 % vs 82 % , P = 0.0003 ) and gastrointestinal symptoms ( 64 % vs 79 % , P = 0.0001 ) compared with patients receiving PEG plus bisacodyl .\